Profile data is unavailable for this security.
About the company
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company has a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
- Revenue in USD (TTM)927.56m
- Net income in USD-579.22m
- Incorporated1998
- Employees988.00
- LocationPTC Therapeutics Inc500 Warren Corporate Center DriveWARREN 07059United StatesUSA
- Phone+1 (908) 222-7000
- Fax+1 (908) 222-7231
- Websitehttps://www.ptcbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Guardant Health Inc | 563.95m | -479.45m | 2.30bn | 1.78k | -- | 14.47 | -- | 4.08 | -4.28 | -4.28 | 5.04 | 1.30 | 0.3321 | 4.00 | 6.06 | 317,002.80 | -28.23 | -22.26 | -31.99 | -24.59 | 59.74 | 64.62 | -85.02 | -97.07 | 6.24 | -12.04 | 0.8778 | -- | 25.45 | 44.14 | 26.76 | -- | 0.2786 | -- |
Geron Corp | 237.00k | -184.13m | 2.31bn | 141.00 | -- | 8.64 | -- | 9,732.34 | -0.3246 | -0.3246 | 0.0004 | 0.455 | 0.0008 | -- | 0.0988 | 1,680.85 | -62.99 | -51.32 | -92.09 | -64.90 | -- | -- | -77,690.72 | -19,949.13 | -- | -- | 0.2484 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
Sana Biotechnology Inc | 0.00 | -283.26m | 2.31bn | 328.00 | -- | 7.18 | -- | -- | -1.46 | -1.46 | 0.00 | 1.45 | 0.00 | -- | -- | 0.00 | -40.81 | -38.99 | -46.74 | -42.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.11 | -- | 112.71 | -- |
Vericel Corp | 197.52m | -3.18m | 2.31bn | 314.00 | -- | 10.12 | 1,476.73 | 11.72 | -0.0684 | -0.0684 | 4.15 | 4.72 | 0.6304 | 4.26 | 3.77 | 629,031.90 | -1.02 | -3.07 | -1.17 | -3.50 | 68.64 | 67.87 | -1.61 | -4.49 | 4.21 | -- | 0.0004 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
Vera Therapeutics Inc | 0.00 | -95.99m | 2.37bn | 51.00 | -- | 18.99 | -- | -- | -2.28 | -2.28 | 0.00 | 2.29 | 0.00 | -- | -- | 0.00 | -62.54 | -- | -74.10 | -- | -- | -- | -- | -- | -- | -- | 0.3291 | -- | -- | -- | -7.79 | -- | -- | -- |
Twist Bioscience Corp | 277.49m | -192.14m | 2.38bn | 919.00 | -- | 4.28 | -- | 8.59 | -3.35 | -3.35 | 4.83 | 9.63 | 0.3565 | 4.87 | 7.04 | 301,943.40 | -24.68 | -30.50 | -27.12 | -33.84 | 38.29 | 36.02 | -69.24 | -113.33 | 5.06 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
CG Oncology Inc | 204.00k | -67.80m | 2.42bn | 61.00 | -- | -- | -- | 11,847.53 | -1.07 | -1.07 | 0.0032 | 2.91 | -- | -- | -- | 3,344.26 | -- | -- | -- | -- | -- | -- | -23,826.96 | -- | -- | -- | 0.002 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
Hims & Hers Health Inc | 872.00m | -23.55m | 2.42bn | 1.05k | -- | 6.99 | -- | 2.77 | -0.1131 | -0.1131 | 4.17 | 1.61 | 2.16 | 7.13 | 195.17 | 833,652.00 | -5.83 | -- | -7.02 | -- | 81.99 | -- | -2.70 | -- | 2.74 | -- | 0.00 | -- | 65.49 | -- | 64.15 | -- | -- | -- |
Denali Therapeutics Inc | 330.53m | -145.22m | 2.44bn | 445.00 | -- | 2.30 | -- | 7.39 | -1.09 | -1.09 | 2.39 | 7.45 | 0.2529 | -- | -- | 742,766.30 | -11.11 | -14.98 | -13.37 | -17.71 | -- | -- | -43.94 | -104.50 | -- | -- | 0.00 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
TG Therapeutics Inc | 289.33m | 41.20m | 2.50bn | 264.00 | 73.43 | -- | 48.03 | 8.64 | 0.2205 | 0.2205 | 1.97 | -- | -- | -- | -- | 1,095,962.00 | -- | -62.87 | -- | -80.06 | 93.53 | -- | 14.24 | -405.03 | -- | 4.01 | -- | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
Avidity Biosciences Inc | 9.56m | -212.22m | 2.53bn | 253.00 | -- | 4.19 | -- | 264.57 | -2.90 | -2.90 | 0.131 | 6.32 | 0.0151 | -- | -- | 37,786.56 | -33.49 | -31.61 | -37.40 | -34.45 | -- | -- | -2,219.88 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
PTC Therapeutics, Inc. | 927.56m | -579.22m | 2.53bn | 988.00 | -- | -- | -- | 2.73 | -7.69 | -7.69 | 12.28 | -11.66 | 0.5459 | 2.33 | 4.64 | 938,823.90 | -34.09 | -26.71 | -48.63 | -33.46 | 92.88 | 93.94 | -62.45 | -83.80 | 1.98 | -0.7975 | 1.72 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
Corcept Therapeutics Incorporated | 523.53m | 118.02m | 2.55bn | 352.00 | 22.93 | 4.66 | 21.39 | 4.86 | 1.07 | 1.07 | 4.74 | 5.27 | 0.822 | 1.12 | 11.13 | 1,487,298.00 | 18.53 | 21.17 | 21.50 | 23.85 | 98.54 | 98.52 | 22.54 | 27.23 | 5.10 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
Neogen Corp | 929.24m | 1.57m | 2.60bn | 2.64k | 1,667.13 | 0.8276 | 22.09 | 2.80 | 0.0072 | 0.0072 | 4.29 | 14.52 | 0.2044 | 2.79 | 5.81 | 351,984.10 | 0.0345 | 3.44 | 0.0355 | 3.62 | 50.97 | 47.25 | 0.1685 | 7.77 | 2.66 | 1.40 | 0.2205 | 0.00 | 56.01 | 15.63 | -147.34 | -- | 25.71 | -- |
Rhythm Pharmaceuticals Inc | 77.43m | -184.68m | 2.67bn | 226.00 | -- | 15.32 | -- | 34.46 | -3.19 | -3.19 | 1.34 | 2.86 | 0.2165 | 1.61 | 7.34 | 342,601.80 | -51.64 | -47.21 | -59.55 | -52.84 | 87.99 | -- | -238.52 | -681.38 | 5.43 | -- | 0.3847 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
Holder | Shares | % Held |
---|---|---|
Wellington Management Co. LLPas of 31 Dec 2023 | 9.82m | 12.81% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 8.61m | 11.24% |
RTW Investments LPas of 31 Dec 2023 | 7.42m | 9.69% |
Armistice Capital LLCas of 31 Dec 2023 | 6.86m | 8.96% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 5.74m | 7.50% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 4.63m | 6.05% |
Camber Capital Management LPas of 31 Dec 2023 | 4.00m | 5.22% |
Cowen & Co. LLCas of 31 Mar 2024 | 3.73m | 4.86% |
Janus Henderson Investors US LLCas of 31 Dec 2023 | 2.58m | 3.37% |
Geode Capital Management LLCas of 31 Dec 2023 | 1.61m | 2.10% |